Metotrexato Accord (Methotrexate)

Methotrexate blocks dihydrofolate reductase, an enzyme needed to produce tetrahydrofolate, a form of folate essential for DNA, RNA and protein synthesis. By limiting these building blocks, the drug reduces the proliferation of immune cells and malignant cells, thereby controlling inflammation and tumor growth.

The dosage of methotrexate is individualized by the prescribing clinician based on the specific indication, patient weight, renal function and treatment response. Only a qualified healthcare professional should determine the appropriate dose and administration schedule.

Methotrexate is classified as pregnancy category X because it can cause fetal malformations and miscarriage. It is contraindicated in pregnancy and women of child‑bearing potential must use reliable contraception. Breastfeeding is also not recommended while receiving methotrexate.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Methotrexate is a folate antagonist, whereas many other immunosuppressants such as biologic agents target specific cytokines or cell surface receptors. Methotrexate is generally less expensive and can be used orally or by injection, but it requires regular laboratory monitoring for liver and bone‑marrow toxicity.

Store Metotrexato Accord at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperature fluctuations to maintain stability and potency.

Metotrexato Accord is supplied as a sterile solution for intra‑arterial, intramuscular or intravenous injection. The route, dose volume and frequency are determined by the treating physician according to the clinical indication and patient characteristics.

Serious risks include severe liver toxicity, pulmonary fibrosis, profound bone‑marrow suppression leading to anemia or infection, and renal failure. Patients should be monitored regularly for liver enzymes, blood counts and kidney function, and any signs of infection or respiratory distress should be reported immediately.

Methotrexate should not be used by pregnant women, individuals with severe liver disease, uncontrolled infections, significant renal impairment, or those with known hypersensitivity to methotrexate or any component of the formulation.